-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, after the release of the 20 articles to optimize epidemic prevention and control, many OTC cold medicines and cough medicines have become the target drugs hoarded by the public, and the market of over-the-counter drugs in the respiratory system of retail pharmacies has become hot again
.
Since the epidemic three years ago, the market pattern has been seriously reshuffled: the sales of 2 billion large items have declined, and CR Sanjiu still holds the champion brand; Online pharmacy sales continued to be hot, with the market share exceeding 10% for the first time, with Ling Pharmaceutical's strong "crown king"
.
The launch of new traditional Chinese medicine drugs has accelerated, and Kangyuan Pharmaceutical has continuously increased its weight to achieve "one-stop" clinical, production and listing, and make every effort to seize the 10 billion market
.
The physical pharmacy exceeded 1 billion products reshuffled, and CR Sanjiu bucked the trend and firmly held the TOP1 brand
According to data from Minai.
com, in 2019, the sales scale of proprietary drugs in the terminal respiratory system of China's urban physical pharmacies was more than 30 billion yuan, and the decrease in passenger flow after the outbreak of the epidemic was superimposed on the impact of prevention and control policies, and the sales scale of this category began to decline gradually in 2020, and is expected to reach 26.
7 billion yuan in 2022, with a market share of more than 20%, which is the best-selling proprietary Chinese medicine category
in physical pharmacy terminals 。
Table 1: Changes of Top 10 Proprietary Drugs in Terminal Respiratory System of Physical Pharmacies in China (CNY 100 million)
Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern
In 2019, the total sales of the TOP10 products in the terminal respiratory system of China's urban physical pharmacies exceeded 10 billion yuan, 9 were OTCs, and 4 exclusive products accounted for 4
.
In 2022, the total sales of TOP10 products are expected to be about 9 billion yuan, 9 are OTC, and 5 are exclusive products
.
The sales of "sales champion" cold spirit granules reached 2.
3 billion yuan in 2019, and the sales of Kyoto Nianci Honey Refining Chuanbei Loquat Paste and Banlan Root Granules also exceeded 1 billion yuan
.
In 2022, it is expected that cold spirit pellets will still rank first, and sales will lose the 2 billion yuan mark after experiencing "three consecutive declines"; Lianhua Qingwen capsules have grown rapidly and have firmly occupied the throne of more than 1 billion products; Banlangen granules have also declined in the past two years, and sales are expected to be at the level
of 800 million yuan this year.
Figure 1: Sales of Lianhua Qingwen capsules (100 million yuan)
Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern
The exclusive product Lianhua Qingwen capsule is a cold medicine, its peak sales in 2020 reached more than 1.
5 billion yuan, in 2021 due to the spread of the epidemic and retail terminal cold fever drug sales restrictions and other factors, the sales of the product fell significantly, with the adjustment of epidemic prevention and control policies, sales in 2022 is expected to stop falling and rebound
。
Figure 2: Sales of iron-coated maple pellets (billion)
Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern
The exclusive product Tin Maple Dou Granules is a cough and expectorant antiasthma medication, which has maintained double-digit growth in China's urban physical pharmacy terminals since 2019, and is expected to exceed 800 million
yuan in sales for the first time in 2022.
If the product can continue to maintain a rapid growth trend, it is expected to become a new item of more than 1 billion in 2024
.
Table 2: Changes of Top 10 Brands of Proprietary Medicines in Terminal Respiratory Systems of Brick-and-mortar Pharmacies in China (CNY 100 million)
Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern
In 2019, the total sales of the top 10 brands of proprietary drugs in the terminal respiratory system of physical pharmacies in China exceeded 8.
3 billion yuan, 9 of which were OTCs and 7 of which were exclusive brands
.
In 2022, the total sales of the TOP10 brands are expected to be about 7.
7 billion yuan, 8 are OTC, and 7 are exclusive brands
.
CR Sanjiu's Cold Spirit Granules successfully topped the top in 2018 and became the top 1 brand of proprietary medicines in the terminal respiratory system of China's urban physical pharmacies, with sales peaking at 2.
2 billion yuan
in 2019.
In recent years, major brands have clashed fiercely, and CR Sanjiu Pharmaceutical's cold spirit granules have always maintained a leading trend and have strong
ability to withstand pressure.
In addition, the company's other cold medicine compound cold spirit granules have not changed much in sales in the three years of the epidemic, and still rank among the top 10 brands, and CR Sanjiu's leading strength in the Chinese proprietary medicine cold medicine market cannot be underestimated
.
The scale of online pharmacies has soared rapidly, and Ling Pharmaceutical has been crowned king for the first time
The epidemic has changed the drug purchase mode of many consumers in the past three years, while e-commerce platforms have also seen opportunities to carry out big promotions and explore new ways of playing, and the scale of drug sales in online pharmacies has continued to rise
.
In 2019, the sales scale of China's online pharmacy terminal respiratory system patent drugs was 400 million yuan, and in 2021 it has risen to 900 million yuan, and the latest data from Minai.
com shows that the sales of this category have exceeded 700 million yuan in the first half of 2022, and it is expected to reach a new high
throughout the year.
In addition, the market share of this category increased by 10% for the first time in the first half of 2022, becoming the top 3 categories
in the online pharmacy terminal proprietary Chinese medicine market.
Table 3: Changes of Top 10 Proprietary Drugs in Terminal Respiratory System of Online Pharmacies in China (: 10,000 yuan)
Note: Sales below 10 million yuan are replaced with *
Source: Minai.
com China's online pharmacy drug terminal competition pattern
In 2019, only 4 of the top 10 proprietary drug products in the terminal respiratory system of China's online pharmacies had sales of more than 10 million yuan, and the total sales of the top 10 products exceeded 165 million yuan, 7 were OTC and 5 were exclusive products
.
In the first half of 2022, the threshold of TOP10 products is 14.
43 million yuan, and the total sales of TOP10 products have exceeded 300 million yuan, 8 are OTC, and 6 are exclusive products
。
Compared with the list before the epidemic, the reshuffle of TOP10 products in the first half of 2022 was serious: the sales of Lianhua Qingwen capsules in 2019 were only 4.
82 million yuan, and they reached 68.
06 million yuan in the first half of 2022, rising from TOP13 in 2019 to TOP1 in the first half of 2022; The sales of iron maple bucket pellets were 6.
11 million yuan in 2019 and 24.
31 million yuan in the first half of 2022, rising from TOP11 in 2019 to TOP5 in the first half of 2022; Lianhua Qingwen granules had sales of 830,000 yuan in 2019, which did not enter the TOP20 list, and reached 19.
85 million yuan in the first half of 2022, rising to TOP6; The sales of bear bile powder in 2019 were only 860,000 yuan, which did not enter the TOP20 list, and rose to 18.
5 million yuan in the first half of 2022, rising to TOP8; The sales of Qiangli Loquat Dew in 2019 were 5.
76 million yuan, which rose to 14.
43 million yuan in the first half of 2022, and its ranking rose from TOP12 in 2019 to TOP10
in the first half of 2022 。
Table 4: Changes in the top 10 brands of proprietary drugs in the terminal respiratory system of China's online pharmacies (million yuan)
Note: Sales below 10 million yuan are replaced with *
Source: Minai.
com China's online pharmacy drug terminal competition pattern
In 2019, only 3 of the top 10 brands of proprietary medicines in the terminal respiratory system of China's online pharmacies had sales of more than 10 million yuan, and the total sales of the top 10 brands exceeded 152 million yuan, 7 were OTCs, and 7 exclusive brands accounted for 7.
In the first half of 2022, the threshold of TOP10 brands is 10.
01 million yuan, and the total sales of TOP10 brands have exceeded 282 million yuan, 7 are OTC, and 8 exclusive brands are accounted for
.
With the rapid rise of Lianhua Qingwen capsules in recent years, Shijiazhuang Yiling Pharmaceutical successfully won the throne of the TOP1 brand of proprietary drugs in the respiratory system in the first half of 2022, and Lianhua Qingwen granules also squeezed into the TOP10 brand list for the first time.
The outbreak of new drugs in the respiratory system has led to the continuous increase of Kangyuan Pharmaceutical
In the past three years of the epidemic, the research and development of proprietary drugs in the respiratory system has continued to rise and has gained a lot of fruit.
Class 6.
1 new drug Lianhua Cough Tablets was approved for marketing in 2020, becoming another blockbuster new product
in this field of Yiling Pharmaceutical.
In November of the same year, Kangyuan Pharmaceutical successfully won the production approval of Yinqiao Qingxing Heat Tablets, which is the first approved new drug in the respiratory system since the implementation of the new Chinese medicine registration classification
.
In October this year, Kangyuan Pharmaceutical's Class 3.
2 new drug Shan Han Shu Wet Granules was approved for marketing for epidemic diseases caused by cold and wet depression, and the latest news said that the product has been sold
offline and online since November 23.
Figure 3: Respiratory new drugs filed for marketing and under review this year
Source: Minai.
com China Declaration Progress (MED) database
Since the beginning of this year, 3 new drugs in the respiratory system have been declared for marketing, and the relevant acceptance numbers are currently under review and approval
.
Kangyuan Pharmaceutical has a new drug rush to market, Lingguishu Gan granules are derived from the ancient classic Fang Linggui Shu Gan Tang, which has significant effects in the treatment of respiratory diseases such as cough, asthma and spitting caused by phlegm
drinking 。
Table 5: New drugs in the respiratory system under research by Kangyuan Pharmaceutical
Source: Minainet Comprehensive Database
In recent years, Kangyuan Pharmaceutical has achieved remarkable research and development results in the field of respiratory system proprietary drugs, and there are currently 5 new drugs actively carrying out clinical trials, involving colds, bronchial asthma, COPD and other indications, the company has formed a clinical, production, listing "one-stop" model, which can continue to deliver new products for the company, KangThe position of Yuan Pharmaceutical in this market is expected to continue to improve
.
Source: Minainet database
Note: Minai.
com's "Competition Pattern of Drug Terminal in China's Urban Physical Pharmacies", the statistical scope is: physical pharmacies in cities at the prefecture level and above nationwide, excluding county and rural pharmacies; Minai.
com's "Competition Pattern of Drug Terminals in China's Online Pharmacies", the statistical scope is: all drug data of online pharmacies nationwide, including all online pharmacy drug data on third-party platforms such as Tmall and Jingdong and private domain platforms; The above sales are calculated based on the average retail price of the product at the online pharmacy
.
Data statistics as of November 23, if there are any omissions, please correct
them.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body). 
